Logo do repositório
 
Publicação

Antibody isotype epitope mapping of SARS-CoV-2 Spike RBD protein

2023-04Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorContreras, Marinela
dc.contributor.authorVicente, Joaquín
dc.contributor.authorCerón, José Joaquín
dc.contributor.authorMartinez Subiela, Silvia
dc.contributor.authorUrra, José Miguel
dc.contributor.authorRodríguez-del-Río, Francisco J.
dc.contributor.authorFerreras-Colino, Elisa
dc.contributor.authorVaz-Rodrigues, Rita
dc.contributor.authorde Fernández de Mera, Isabel G.
dc.contributor.authorAntunes, Sandra
dc.contributor.authorDomingos, Ana
dc.contributor.authorGortázar, Christian
dc.contributor.authorde la Fuente, José
dc.contributor.institutionInstituto de Higiene e Medicina Tropical (IHMT)
dc.contributor.institutionVector borne diseases and pathogens (VBD)
dc.contributor.institutionGlobal Health and Tropical Medicine (GHTM)
dc.contributor.pblWiley-VCH Verlag
dc.date.accessioned2023-06-23T22:24:15Z
dc.date.available2023-06-23T22:24:15Z
dc.date.issued2023-04
dc.descriptionFunding Information: This study was supported by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain and EU‐FEDER [Grant BIOGAL PID2020‐116761GB‐I00]. M.C. was funded by the Ministerio de Ciencia, Innovación y Universidades, Spain, grant IJC2020‐042710‐I. RV‐R was funded by Universidad de Castilla‐La Mancha (UCLM), Spain and the European Social Fund (ESF) [grant 2022‐PRED‐20675]. Funding Information: This study was supported by Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación, Spain and EU-FEDER [Grant BIOGAL PID2020-116761GB-I00]. M.C. was funded by the Ministerio de Ciencia, Innovación y Universidades, Spain, grant IJC2020-042710-I. RV-R was funded by Universidad de Castilla-La Mancha (UCLM), Spain and the European Social Fund (ESF) [grant 2022-PRED-20675]. Publisher Copyright: © 2023 The Authors. European Journal of Immunology published by Wiley-VCH GmbH.
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still poses a challenge for biomedicine and public health. To advance the development of effective diagnostic, prognostic, and preventive interventions, our study focused on high-throughput antibody binding epitope mapping of the SARS-CoV-2 spike RBD protein by IgA, IgM and IgG antibodies in saliva and sera of different cohorts from healthy uninfected individuals to SARS-CoV-2-infected unvaccinated and vaccinated asymptomatic, recovered, nonsevere, and severe patients. Identified candidate diagnostic (455-LFRKSNLKPFERD-467), prognostic (395-VYADSFVIRGDEV-407-C-KLH, 332-ITNLCPFGEV-342-C-KLH, 352-AWNRKRI-358-C-KLH, 524-VCGPKKSTNLVKN-536-KLH), and protective (MKLLE-487-NCYFPLQSYGFQPTNGVG-504-GGGGS-446-GGNYNYLYRLFRKSNLKPFERD-467) epitopes were validated with sera from prevaccine and postvaccine cohorts. The results identified neutralizing epitopes and support that antibody recognition of linear B-cell epitopes in RBD protein is associated with antibody isotype and disease symptomatology. The findings in asymptomatic individuals suggest a role for anti-RBD antibodies in the protective response against SARS-CoV-2. The possibility of translating results into diagnostic interventions for the early diagnosis of asymptomatic individuals and prognosis of disease severity provides new tools for COVID-19 surveillance and evaluation of risks in hospitalized patients. These results, together with other approaches, may contribute to the development of new vaccines for the control of COVID-19 and other coronavirus-related diseases using a quantum vaccinomics approach through the combination of protective epitopes.en
dc.description.versionpublishersversion
dc.description.versionpublished
dc.format.extent17
dc.format.extent4656754
dc.identifier.doi10.1002/eji.202250206
dc.identifier.issn0014-2980
dc.identifier.otherPURE: 64220256
dc.identifier.otherPURE UUID: 336fa04f-e111-4486-bb07-88ce2e417a6b
dc.identifier.otherScopus: 85147339828
dc.identifier.otherPubMed: 36658749
dc.identifier.otherWOS: WOS:000926901900001
dc.identifier.otherORCID: /0000-0002-5512-9093/work/151367065
dc.identifier.urihttp://hdl.handle.net/10362/154354
dc.identifier.urlhttps://www.scopus.com/pages/publications/85147339828
dc.language.isoeng
dc.peerreviewedyes
dc.subjectantibody isotype
dc.subjectepitope mapping
dc.subjectprognostic, SARS-CoV-2
dc.subjectspike protein
dc.subjectRA0421 Public health. Hygiene. Preventive Medicine
dc.subjectQR355 Virology
dc.subjectQR Microbiology
dc.subjectQR180 Immunology
dc.subjectInfectious Diseases
dc.subjectImmunology and Allergy
dc.subjectImmunology
dc.subjectSDG 3 - Good Health and Well-being
dc.subjectSDG 9 - Industry, Innovation, and Infrastructure
dc.titleAntibody isotype epitope mapping of SARS-CoV-2 Spike RBD proteinen
dc.title.subtitleTargets for COVID-19 symptomatology and disease controlen
dc.typejournal article
degois.publication.issue4
degois.publication.titleEuropean Journal of Immunology
degois.publication.volume53
dspace.entity.typePublication
rcaap.rightsopenAccess

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Antibody_isotype_epitope_mapping_of_SARS_CoV_2_Spike_RBD_protein_Targets_for_COVID_19.pdf
Tamanho:
4.44 MB
Formato:
Adobe Portable Document Format
Ver/Abrir

Coleções

Home collection (IHMT)